• Explore /
  • Poster
  • / Outcomes of patients with relapsed and refractory chronic lymphocytic leukemia (CLL) who discontinue idelalisib treatment.

Outcomes of patients with relapsed and refractory chronic lymphocytic leukemia (CLL) who discontinue idelalisib treatment.

Abstract Poster

Authors

Jennifer Brown

Jennifer R. Brown

Dana-Farber Cancer Institute, Boston, MA

Jennifer R. Brown , Paolo Ghia , Jeffrey Alan Jones , Andrew Pettitt , Jeff Porter Sharman , Loic Ysebaert , Stephan Stilgenbauer , Yeonhee Kim , Terry Newcomb , Nai-Shun Yao , Richard R. Furman

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Sub Track

Chronic Lymphocytic Leukemia (CLL) and Hairy Cell

Clinical Trial Registration Number

NCT01539512, NCT01539291, NCT01659021

Citation

J Clin Oncol 34, 2016 (suppl; abstr 7531)

DOI

10.1200/JCO.2016.34.15_suppl.7531

Abstract #

7531

Poster Bd #

87

Abstract Disclosures

Similar Posters

First Author: Jeffrey Alan Jones

First Author: Wojciech Jurczak

First Author: Jacob Drobnyk Soumerai

First Author: Jacqueline Claudia Barrientos